Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.

American journal of clinical pathology - 1 May 2011

Dunlap Jennifer, Kelemen Katalin, Leeborg Nicky, Braziel Rita, Olson Susan, Press Richard, Huang James, Gatter Ken, Loriaux Marc, Fan Guang

Abstract excerpt

Myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms are heterogeneous disorders. JAK2 mutation testing and karyotyping are routinely used for diagnosis but have not been incorporated into risk stratification in Philadelphia chromosome-negative myeloproliferative neoplasm...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosomes, Human, Pair 13
Share to Chromosomes, Human, Pair 20

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 21

Share to Chromosomes, Human, Pair 7

Share to Chromosomes, Human, Pair 9

Share to Janus Kinase 2

Share to Myelodysplastic-Myeloproliferative Diseases

Share to Myeloproliferative Disorders

Source

Identifiers

PMID: 21502425
DOI: 10.1309/AJCPS6C8EVYCQNRM

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21502425-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.PMID 21502425Read ↗

Jak-2 positive myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2 inhibition for the treatment of hematologic and solid malignanciesSemantic proximity Read ↗

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overviewSemantic proximity Read ↗

Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.Semantic proximity Read ↗

JAK2: implications for diagnosis and classification of myeloproliferative disorders.Semantic proximity Read ↗

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasmsSemantic proximity Read ↗

Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation.Semantic proximity Read ↗

JAK/STAT Pathways in Cytokine Signaling and Myeloproliferative Disorders: Approaches for Targeted TherapiesSemantic proximity Read ↗

Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.Semantic proximity Read ↗

Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Semantic proximity Read ↗

JAK2 inhibitors and myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.